This study is about a treatment called MK-2214 for early Alzheimer's Disease (AD), which affects memory, speech, and decision-making. Researchers want to see if MK-2214 can slow the spread of a protein called tau in the brain, which harms brain cells in AD. A placebo will be used to compare results; it looks like MK-2214 but has no active ingredients.
Participants need to have mild memory issues due to AD and a study partner. They should not have had a stroke, certain brain diseases, seizures, or recent serious illnesses. They should be able to have brain scans like CT, PET, or MRI. People living in nursing homes or needing constant care are not eligible.
- Participants will undergo visits and tests to monitor their brain activity and health.
- Researchers will check if participants can tolerate MK-2214 safely.
- Participants must have stable medication for any existing AD therapy for 3 months before joining.
How understandable was the trial content above?
Hard to understand
Easy to understand